Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017

September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the...

U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017

September 8, 2017 — Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the...

Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017

September 5, 2017 — Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC)...

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017

August 16, 2017 — In the featured translational article in the August issue of ...

Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis
News | Biopsy Systems | July 17, 2017

July 17, 2017 — Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical...

Augmenix Announces First New Zealand Prostate Cancer Patient Treated with SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | June 28, 2017

June 28, 2017 — Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR...

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017

An estimated one in seven American men will be affected by...

Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017

In the battle against metastatic ...

Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017

May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...

FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017

May 15, 2017 — Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be...

News | Prostate Cancer | April 24, 2017

April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal...

MRI

Multiparametric MRI (MpMRI) has proved helpful in enhancing biopsy sampling for prostate cancer when combined with ultrasound. 

Feature | Prostate Cancer | April 10, 2017 | By Jeff Zagoudis

While prostate cancer is one of the most common cancers among American men — the third leading cause of cancer...

News | Prostate Cancer | April 04, 2017

April 4, 2017 — Profound Medical Corp. announced that the first TULSA-PRO patient paid procedure has been...

Analogic, bkFusion, bk3000, MRI-ultrasound fusion, prostate biopsy, EAU 2017
News | Biopsy Systems | March 30, 2017

March 30, 2017 — Analogic Corp. announced that it will introduce its bkFusion solution for improving biopsy...

high-intensity focused ultrasound, HIFU, prostate tissue ablation, after radiotherapy, EDAP TMS SA, Ablatherm, British Journal of Urology International study
News | Focused Ultrasound Therapy | March 29, 2017

March 29, 2017 — EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic...

VERT, virtual environment radiotherapy, radiation therapy, patient anxiety, Thomas Jefferson University study
News | Radiation Therapy | March 27, 2017

March 27, 2017 — Radiation therapists and physicians know that education can reduce anxiety before radiation...

Karmanos Cancer Institute, UroNav Fusion Biopsy System, prostate cancer
News | Biopsy Systems | March 23, 2017

March 23, 2017 — Urology specialists at the Barbara Ann Karmanos Cancer Institute (Detroit) have begun using the...

News | Prostate Cancer | March 22, 2017

March 22, 2017 — Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO...

Exact Imaging, Health Canada approval, ExactVu micro-ultrasound system, prostate biopsies, Sunnybrook Health Sciences Centre, Gregory Czarnota
News | Biopsy Systems | March 16, 2017

March 16, 2017 — Exact Imaging has received Health Canada approval and the corresponding medical device license (#...

PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017

March 16, 2017 — The featured clinical investigation article of the March 2017 issue of the ...